SCHEMBL7120855

SCHEMBL7120855

Oc1cc(O)cc(C(O)C(Cl)(Cl)Cl)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.40
ADRB2 P07550 8/20 0.39
LMNA P02545 4/20 0.39
HIF1A Q16665 3/20 0.39
KMT2A Q03164 3/20 0.39
TSHR P16473 2/20 0.39
CASP7 P55210 2/20 0.39
CYP3A4 P08684 2/20 0.39
CYP2C9 P11712 1/20 0.39
ESR1 P03372 1/20 0.39
ESR2 Q92731 1/20 0.39
ADRA1A P35348 1/20 0.36
MEN1 O00255 2/20 0.34
BLM P54132 2/20 0.34
KDM4E B2RXH2 1/20 0.34
CASP1 P29466 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
APEX1 P27695 1/20 0.32
HPGD P15428 1/20 0.31
CRHBP P24387 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7125044 0.78 GABRA1 (0.35) ADRB2LMNAHIF1AKMT2ATSHR
SCHEMBL3697805 0.78 ADRB1 (0.48) ADRB2LMNAHIF1ATSHRCYP3A4
SCHEMBL7121112 0.75 ESR1 (0.41) BACE1ADRB2LMNAHIF1AKMT2A
SCHEMBL7120983 0.75 ESR1 (0.62) LMNAHIF1AKMT2ATSHRCYP3A4
SCHEMBL7122077 0.75 ACHE (0.42) LMNAHIF1AKMT2ATSHRCYP3A4
SCHEMBL7122682 0.73 ESR1 (0.33) BACE1LMNAKMT2ACYP3A4ESR1
SCHEMBL23149890 0.71 CES2 (0.44)
SCHEMBL7120793 0.70 ABL1 (0.42) LMNAKMT2ATSHRCYP3A4CYP2C9
SCHEMBL7128500 0.70 TDP1 (0.48) ADRB2LMNAHIF1AKMT2ATSHR
SCHEMBL23172257 0.70 CES2 (0.40) KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030144541-A1 Process for preparing alpha-halogenated retones RHODIA CHIMIE (FR) 2003-07-31 US claimed
EP-1250303-A1 METHOD FOR PREPARING ALPHA-HALOGENATED KETONES RHODIA CHIMIE (FR) 2002-10-23 EP claimed
WO-2001055067-A1 METHOD FOR PREPARING ALPHA-HALOGENATED KETONES RHODIA CHIMIE (FR) 2001-08-02 WO claimed
US-20030144541-A1 Process for preparing alpha-halogenated retones RHODIA CHIMIE (FR) 2003-07-31 US disclosed
EP-1250303-A1 METHOD FOR PREPARING ALPHA-HALOGENATED KETONES RHODIA CHIMIE (FR) 2002-10-23 EP disclosed
WO-2001055067-A1 METHOD FOR PREPARING ALPHA-HALOGENATED KETONES RHODIA CHIMIE (FR) 2001-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144541-A1 Process for preparing alpha-halogenated retones ADH1A, ADH1C, RER1 BACE1 3269/4885ADRB2 1281/4885LMNA 2235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.